Over the past decade, there has been an explosion of research uncovering the critical role the lymphatic system plays in serious diseases affecting more than 500 million people globally. The opportunity to address this need is immense, and Ropirio is at the forefront, having identified the first target that activates the lymphatic system. This activation improves lymphatic flow, modulates inflammation, and prevents fibrosis. Ropirio is singularly focused on developing the first lymphatic medicines to improve patients’ lives.
Company Details
- Employees
- 4
- Founded
- 2023
- Address
- This Need Is Immense
- Industry
- Biotechnology Research
- NAICS
-
Research and Development in Biotechnology (except Nanobiotechnology)
Ropirio Therapeutics, Inc. Questions
Ropirio Therapeutics, Inc.'s LinkedIn profile is https://www.linkedin.com/company/ropirio
Ropirio Therapeutics, Inc. has
4 employees.
View email and phone details for 4
employees at Ropirio Therapeutics, Inc..
Ropirio Therapeutics, Inc.'s industry is
Biotechnology Research
Ropirio Therapeutics, Inc.'s top competitors are
Amplifyer Bio,
Port Therapeutics,
Satellite Bio,
Vironexis Biotherapeutics,
Sunbird Bio,
Bioivt,
Inaya Therapeutics,
Matrisome Bio,
Hepregen Corporation,
Wyss Institute At Harvard University.
Ropirio Therapeutics, Inc.'s categories are Biotechnology Research
Ropirio Therapeutics, Inc.'s founding year is 2023
